Answers are grounded in this paper and cite their sources.
Investigates predictive modeling for treatment response and survival in hepatocellular carcinoma, suggesting distinct biological drivers.
Background & Aims: While combined interventional therapies and targeted immunotherapy have improved outcomes for unresectable hepatocellular carcinoma (HCC), radiographic tumor shrinkage does not guarantee prolonged survival (the “responder paradox”). We hypothesized that these distinct endpoints may be associated with different clinical and biological factors and require separate predictive strategies. This study aimed to develop the predictive radiomics-integrated multimodal estimation (PRIME) system to independently predict and biologically characterize treatment response versus overall survival (OS). Methods: In this multicenter study comprising 246 patients receiving combined interventional therapies and targeted immunotherapy, we integrated clinical data and dual-phase CT radiomics. We employed multimodal fusion algorithms to construct two models: PRIME-R (predicting 3-month objective response) and PRIME-S (predicting OS). Model performance was rigorously tested in an external validation cohort. Furthermore, we utilized SHapley Additive exPlanations and matched imaging-transcriptomic data to elucidate the specific clinical and molecular features associated with each outcome. Results: The PRIME models demonstrated superior accuracy compared to single-modality approaches. In external validation, PRIME-R achieved an AUC of 0.85, while PRIME-S achieved a C-index of 0.72. Significant risk stratification was confirmed (HR = 3.31, 95% CI: 2.06– 5.31, P < 0.001). Crucially, feature analysis revealed a distinct divergence: PRIME-R was primarily driven by tumor morphology. In contrast, PRIME-S relied heavily on systemic inflammation and liver function reserve. Transcriptomic profiling supported this interpretation, showing that response was associated with acute immune activation, whereas survival was associated with metabolic adaptation and tissue homeostasis. Conclusion: Short-term response and long-term survival in HCC are distinct clinical endpoints associated with different biological drivers. The PRIME system effectively distinguishes these outcomes, offering insights into the responder paradox and supporting dual-endpoint risk stratification pending further prospective validation. The diagram illustrates the relationship between tumor shrinkage and durable survival, highlighting the responder paradox. It begins with a liver showing tumor shrinkage due to combined therapy, which includes medication and radiomics and clinical data. Despite shrinkage, durable survival is not guaranteed, indicated by the responder paradox. The PRIME-RESPONSE section involves tumor geometry and immune activation. The PRIME-SURVIVAL section includes liver function and heterogeneity and metabolic adaptation. A grid shows outcomes: ideal outcome with shrinkage and stable survival and paradoxical outcome with primary resistance despite shrinkage.Diagram of tumor shrinkage, survival and responder paradox in cancer therapy.
No takes yet. Share an insight, caveat, or question.
Lu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: